Vifor Pharma Ltd.'s Form 4 filing
ChemoCentryx, Inc. · filed Oct 13, 2021
- Accession no.
- 0000899243-21-040141
- Filed
- Oct 13, 2021, 7:05 PM ET
- Trade date
- Oct 12, 2021
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $157.7M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vifor Pharma Ltd.CIK 0001416422 | 10% Owner |
| Vifor (International) LtdCIK 0001675217 | 10% Owner |
| Vifor Fresenius Medical Care Renal Pharma Ltd.CIK 0001757924 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2021 | Common Stock, par value $0.001 per share | SSaleDisposed | −4,000,000 | $39.43 | −$157,720,000 | 5,194,085 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.